Pharvaris (PHVS) stock
PHVS's Quality Score fell 2 points on Mon, Nov 2, to 3.
Follow PHVS's news. Pro members can get an alert when Pharvaris files news, and see its trials, share raises, and its CEO's filings.
We do the work for you. Every stock is scored and ranked, every 15 seconds while the market is open. Here it's 15 minutes behind. Pro members see it live.
Key facts on PHVS
| Holding it back | A €176M loss |
| Latest filing | 424B5, May 8 |
What's next
Mon Nov 9: Guggenheim 3rd Annual Global…Investor conference · date confirmed.
1 more date ahead: the conference, for Pro members.
PHVS catalysts
After its last 4 reports it closed +3.8% on average, higher 3 of 4 times.
What's next for PHVS, and how long its cash lasts
Next step the company has named
Cash runway
EUR 292M in cash
Dilution on the horizon
- Shelf registration (F-3ASR, filed Apr 12, 2024)
- At-the-market share sales program (F-3ASR, filed Apr 12, 2024)
Insiders
Director Viviane Monges sold 11,969 shares on Sep 23. 42 more insider trades this year.
FDA dates in the next 60 days
Decision dates and advisory committee meetings the companies have announced in their filings, soonest first and small companies first.
- In 20 days
CAPRCapricor Therapeutics
- In 20 days
SVRASavara
- In 50 days
MLYSMineralys Therapeutics
Why PHVS scores 3
Below Averagefor quality, not price, 3 of 14 chart checks firingWhat the Quality Score means
- +3Chart checks 3 of 14 firing right now, one point each
- +2Long-term trend above a rising 200-day average
- Profit subtracts
- Insider trades subtracts
Here is what Pro members see.
- Prices refresh every 2.5 seconds during market hours.
- Optional alerts by push, email, or the bell.
- Add it to your Home Screen and it opens like an app.
PHVS has 3 of 14 chart checks firing
PHVS RSI today: 59.6, below its 50-day, above its 200-day
- RSI 1459.6
- MACD (12, 26, 9)Above signal
- 50-day average$33.61
- 200-day average$31.03
- 50/200 crossGolden cross
- ADX 1417.4
- Support$33.01
- Resistance$35.54
- 52-week high$43.25
- 52-week low$21.02
- Chart patternNone
- Bollinger Bands (20, 2)Inside
- Volume0.9x
The deep dive on PHVS
- What it does and how it makes money
- Who holds and trades itForm 4, filed Sep 21, 2026
How PHVS ranks in Pharma
PHVS is #39 of 92 by Quality Score.
| 1 | ||
| 2 | ||
| 3 | ||
| Open for its score | ||
| Open for its score | ||
| Open for its score | ||
| Open for its score | ||
| 39 |
When does PHVS report earnings, and what happens after?
Expected to report Thu Nov 12, before the open (in 10 days). Expected.
What an earnings report is: every 3 months, a company tells everyone how much it sold and earned. We read the figures, the outlook, and how the stock moved after.
| Reported | Gap | Reaction | 5 sessions |
|---|---|---|---|
| Aug 12, 2026 | -1.1% | +5.9% | +4.9% |
| May 12, 2026 | +2.5% | +5.4% | -7.4% |
| Apr 2, 2026 | -4.5% | -3.0% | -8.1% |
Insiders trading PHVS
PHVS insider trades
9 insiders sold $17.7M across 18 filings in the last 6 months. No open-market buys on record. The newest:
PHVS's officers and directors
Officers and directors with a Form 4 in the last 12 months.
About Pharvaris
Pharvaris NV is a late-stage biopharmaceutical company which is engaged in developing novel, oral bradykinin B2 receptor antagonists to prevent and treat HAE attacks. By directly pursuing this clinically therapeutic target with novel small molecules, With positive data in both Phase 2 prophylaxis and studies in HAE, Pharvaris is developing deucrictibant. Pharvaris is currently enrolling a pivotal Phase 3 study for the treatment of HAE attacks and plans to initiate a pivotal Phase 3 study of deucrictibant for the prevention of HAE attacks. The company is also running open-label extension studies in both on-demand (RAPIDe-2) and prophylactic (CHAPTER-4) settings to collect long-term safety and efficacy data in HAE patients.
PHVS's score card
Pro members see every line of every stock's score.
- What would turn PHVS's score around: 5 things
- 5 more filings explained, a plain line each
- Real-time prices, no delay
Straight Answers
Is PHVS a good stock to buy? What its Quality Score says
PHVS scores 3 today, which Breakaway calls Below Average. It is #39 of 92 in Pharma by Quality Score, with 3 of 14 chart checks firing. Breakaway does not say whether to buy any stock: the score does not know your situation, and it is not a recommendation to buy or sell anything. Please do your own research.
What is PHVS's Quality Score?
PHVS scores 3 today, which Breakaway calls Below Average (0 to 5). That is #39 of 92 in Pharma by Quality Score. The score adds up the chart checks, the trend, the company's filed sales, its profits, the news, insider trades, and Congress trades. The section above lists the lines behind PHVS's 3.
Are insiders buying PHVS?
9 insiders sold $17.7M across 18 filings in the last 6 months. No open-market buys on record. The newest is Viviane Monges, Director, who sold $396K on Sep 23. Every filing, with the scored weight, for Pro members.
Are the prices delayed?
Only on the public pages, which run at least 15 minutes behind. Pro members, and anyone on a guest pass, see real-time prices: the scanner refreshes every 15 seconds, and your watchlist every few seconds, pre-market and after hours included.